Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Common Equity (2016 - 2021)

Historic Common Equity for ENDRA Life Sciences (NDRA) over the last 6 years, with Q3 2021 value amounting to $13.2 million.

  • ENDRA Life Sciences' Common Equity rose 29448.69% to $13.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was $13.2 million, marking a year-over-year increase of 29448.69%. This contributed to the annual value of $7.2 million for FY2020, which is 5059.48% up from last year.
  • ENDRA Life Sciences' Common Equity amounted to $13.2 million in Q3 2021, which was up 29448.69% from $15.0 million recorded in Q2 2021.
  • ENDRA Life Sciences' 5-year Common Equity high stood at $17.9 million for Q1 2021, and its period low was -$1.4 million during Q1 2017.
  • Over the past 5 years, ENDRA Life Sciences' median Common Equity value was $3.8 million (recorded in 2019), while the average stood at $5.3 million.
  • Per our database at Business Quant, ENDRA Life Sciences' Common Equity tumbled by 10638.43% in 2018 and then skyrocketed by 143446.68% in 2021.
  • Over the past 5 years, ENDRA Life Sciences' Common Equity (Quarter) stood at $5.3 million in 2017, then grew by 18.44% to $6.2 million in 2018, then decreased by 23.81% to $4.8 million in 2019, then surged by 50.59% to $7.2 million in 2020, then surged by 83.51% to $13.2 million in 2021.
  • Its Common Equity stands at $13.2 million for Q3 2021, versus $15.0 million for Q2 2021 and $17.9 million for Q1 2021.